Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
Aged
Biomarkers, Tumor
/ genetics
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Japan
Male
Middle Aged
Mutation
/ genetics
Neoplasms
/ drug therapy
Phosphatidylinositol 3-Kinases
/ genetics
TOR Serine-Threonine Kinases
/ genetics
Tumor Suppressor Protein p53
/ genetics
Exome Sequencing
Japanese Cancer Genome Atlas
TMB ultralow
TP53 inactivation
gene expression signature
tumor mutational burden
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
06
05
2020
revised:
06
07
2020
accepted:
06
07
2020
pubmed:
15
7
2020
medline:
16
12
2020
entrez:
15
7
2020
Statut:
ppublish
Résumé
Tumor mutational burden analysis using whole-exome sequencing highlights features of tumors with various mutations or known driver alterations. Cancers with few changes in the exon regions have unclear characteristics, even though low-mutated tumors are often detected in pan-cancer analysis. In the present study, we analyzed tumors with low tumor mutational burden listed in the Japanese version of The Cancer Genome Atlas, a data set of 5020 primary solid tumors. Our analysis revealed that detection rates of known driver mutations and copy number variation were decreased in samples with tumor mutational burden below 1.0 (ultralow tumor), compared with those in samples with low tumor mutational burden (≤5 mutations/Mb). This trend was also observed in The Cancer Genome Atlas data set. In the ultralow tumor mutational burden tumors, expression analysis showed decreased TP53 inactivation and chromosomal instability. TP53 inactivation frequently correlated with PI3K/mTOR-related gene expression, implying suppression of the PI3K/mTOR pathway in ultralow tumor mutational burden tumors. In common with mutational burden, the T cell-inflamed gene expression profiling signature was a potential marker for prediction of an immune checkpoint inhibitor response, and some ultralow tumor mutational burden tumor populations highly expressed this signature. Our analysis focused on how these tumors could provide insight into tumors with low somatic alteration that are difficult to detect solely using whole-exome sequencing.
Identifiants
pubmed: 32662546
doi: 10.1111/cas.14572
pmc: PMC7540986
doi:
Substances chimiques
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3893-3901Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 27329033
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nature. 2020 Jun;582(7810):100-103
pubmed: 32461694
Biomed Res. 2016;37(6):367-379
pubmed: 28003584
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Mol Cells. 2015 Sep;38(9):789-95
pubmed: 26242195
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-50
pubmed: 20876136
Cancer Metastasis Rev. 2008 Jun;27(2):123-35
pubmed: 18265945
EBioMedicine. 2018 Aug;34:35-45
pubmed: 30037719
Sci Rep. 2017 Apr 4;7(1):641
pubmed: 28377632
Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
Cell Rep. 2019 Jul 30;28(5):1370-1384.e5
pubmed: 31365877
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Cell Rep. 2018 Oct 23;25(4):1066-1080.e8
pubmed: 30355485
Breast Cancer Res. 2010;12(3):R40
pubmed: 20569503
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
JCI Insight. 2018 Feb 22;3(4):
pubmed: 29467336
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Biomed Res. 2016;37(6):359-366
pubmed: 28003583
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Nat Med. 2019 Mar;25(3):517-525
pubmed: 30664780
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W449-60
pubmed: 24906883
PLoS Comput Biol. 2015 Nov 19;11(11):e1004618
pubmed: 26583378
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6010-E6019
pubmed: 29895694
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Nature. 2020 Jun;582(7810):95-99
pubmed: 32494066
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Exp Clin Cancer Res. 2010 Oct 11;29:133
pubmed: 20937111
Cancer Cell. 2017 Jun 12;31(6):820-832.e3
pubmed: 28528867
J Physiol. 2017 Jul 15;595(14):4845-4855
pubmed: 28464351
Biomed Res. 2016;37(1):51-62
pubmed: 26912140
Onco Targets Ther. 2019 Dec 04;12:10639-10650
pubmed: 31824171
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Oncotarget. 2017 Apr 18;8(16):27277-27285
pubmed: 28460482
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nat Rev Cancer. 2014 Dec;14(12):786-800
pubmed: 25568919
Cancer Metastasis Rev. 1995 Mar;14(1):43-8
pubmed: 7606820
Curr Opin Oncol. 1995 Jan;7(1):69-75
pubmed: 7696366
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Cancer Sci. 2020 Feb;111(2):687-699
pubmed: 31863614
Biomed Res. 2018;39(3):159-167
pubmed: 29899191
Cancer Sci. 2020 Oct;111(10):3893-3901
pubmed: 32662546
Cancer Sci. 2019 Aug;110(8):2620-2628
pubmed: 31152682